10x Genomics introduced the next‑generation Chromium Flex assay, capable of profiling up to 384 samples and 100 million cells per week using a 96‑well plate format.
The new assay builds on 10x’s proven chemistry, delivering higher sensitivity and sequencing efficiency while reducing reagent waste. Automation compatibility allows integration with liquid‑handling systems, streamlining workflows for academic and biopharma customers.
Early adopters report faster throughput and lower per‑sample cost, positioning the assay as a game‑changer for large‑scale CRISPR screens and FFPE‑based studies. The launch expands 10x’s single‑cell portfolio and reinforces its competitive moat in the market.
The product is now available globally. 10x Genomics will report its third‑quarter 2025 financial results on November 6, 2025, and has recently partnered with Anthropic to integrate its analysis tools into the Claude for Life Sciences platform.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.